ABBVIE

AbbVie's $1.4 billion acquisition of Aliada Therapeutics positions them to advance ALIA-1758, a potentially best-in-class Alzheimer's therapy using novel BBB-crossing technology. This strategic move into neuroscience aims to address critical unmet needs and sets AbbVie on the frontier of CNS innovation.

AbbVie's $1.4 billion acquisition of Aliada Therapeutics positions them to advance ALIA-1758, a potentially best-in-class Alzheimer's therapy using novel BBB-crossing technology. This strategic move into neuroscience aims to address critical unmet needs and sets AbbVie on the frontier of CNS innovation.

The Orphan Indication Drugs market, focusing on rare diseases, is driven by government support and investment, offering lucrative opportunities for pharmaceutical companies. Key players include Bristol-Myers Squibb, Roche, Novartis, and Johnson & Johnson. The market is segmented by type (biologics, non-biologics) and application (hospital pharmacy, retail pharmacy, online sales), with growth potential in both established and emerging markets.

Kivu Biosciences raised $92M in Series A to advance its ADC technology, aiming for more precise and stable drugs to reduce side effects, with plans for a solid tumor clinical trial in 2024. Novo Holdings led the round, joined by six other venture firms.

Upadacitinib (Rinvoq) demonstrated a favorable long-term benefit-risk profile through 76 weeks in adolescents with moderate to severe atopic dermatitis, achieving EASI-75 in 84-96% of patients across three phase III trials. Both 15 mg and 30 mg doses met primary endpoints, with acne and nausea as most common adverse events. Long-term outcomes were consistent with known AE profile, with no new signals observed. The analysis involved 542 adolescents, with data gathered from August 2018 to April 2022.

AbbVie and Gedeon Richter expand their neuropsychiatric collaboration, aiming to discover and develop novel targets. The partnership includes preclinical and clinical R&D activities, with Richter receiving an upfront payment of $25 million and potential milestone payments. Vraylar, a product of their previous collaboration, has been approved for schizophrenia, bipolar I disorder, major depressive disorder, and as adjunctive therapy for MDD. The prevalence of mental illness in the U.S. in 2022 was over 20%, highlighting the need for new therapies.

Newly described lymph node-like structures in liver tumors after immunotherapy may be crucial for treating hepatocellular carcinoma, potentially increasing the likelihood of curing the cancer, according to a study by Johns Hopkins researchers.

Amgen sets $1,665 list price for biosimilar Eylea, launching Pavblu without legal settlement. GSK invests $800 million in U.S. manufacturing expansion. Roche partners with Dyno Therapeutics for neurological gene therapy. AbbVie and Gideon Richter collaborate on neuropsychiatric treatments. Marinus Pharmaceuticals faces strategic review after Phase 3 seizure drug trial failure.

FDA approves AbbVie's Vyalev (foscarbidopa and foslevodopa) for advanced Parkinson’s disease, offering the first subcutaneous, 24-hour levodopa-based infusion in the US. Vyalev aims to manage motor fluctuations and dyskinesia, with a Phase III trial showing increased 'on' time without dyskinesia. Adverse reactions are mild to moderate, and coverage for Medicare patients is expected in 2025.

FDA approved Vyalev, a 24-hour subcutaneous infusion of foslevodopa/foscarbidopa for Parkinson’s disease motor fluctuations, produced by AbbVie. This soluble form of carbidopa/levodopa provides steady blood levels of levodopa. A clinical trial showed significant reductions in OFF time and increases in ON time without dyskinesias compared to immediate-release carbidopa/levodopa. Insurance coverage for Vyalev is evolving, and it may be suitable for those with advanced PD.